Changing Landscape of DLBCL Treatment: ADCs, Bispecific Antibodies, CAR T Therapies, and Combinations – Enduring Webcast

Description

Program Description

---

This enduring webcast will provide up-to-date, evidence-based information for diagnosing and treating patients with DLBCL.

To better define classification, molecular characterization, genetic subtypes, risk stratification, and managing diffuse large B cell lymphoma (DLBCL) with antigen-drug conjugates (ADCs), bispecific antibodies (BsAbs), chimeric antigen receptor T-cell (CAR T), an oral selective inhibitor of exportin 1 (XPO1) therapies, and best practices for managing AEs. This activity will focus on the following:

• DLBCL – Classification, molecular characterization, genetic subtypes of DLBCL.
  • Cell of origin (COO) – Gene expression profiling (GEP) of regular and DLBCL cells
  • Molecular Features – The C-MYC is a proto-oncogene located in chromosome 8q24
  • Genetic Subtypes – Categories include the MCD, BN2, N1, and EZB subtypes.
• Risk stratification – PET/CT imaging and circulating tumor DNA in prognosticating patients with DLBCL.
• Upfront Therapy – Chemo-chemoimmunotherapy with R-CHOP +/− radiation for limited-stage disease
• Relapsed/refractory (R/R) DLBCL – Novel therapies such as ADCs, CAR T, BsAbs, and XPO1
  • Antigen-Drug Conjugates (ADCs)
    • Brentuximab vedotin in combination with lenalidomide, and rituximab
    • Polatuzumab vedotin in addition to rituximab-bendamustine (BR) or BR alone
    • Loncastuximab tesirine as a single agent
    • Tafasitamab in combination with lenalidomide, bendamustine and R-CHOP
  • Bispecific Antibodies (BsAbs)
    • Mosunetuzumab, Glofitamab, Epcoritamab, and Odronextamab
  • Protein kinase C-beta inhibitor
    • Enzastaurin
  • CAR T-Cell Therapies
    • Axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel)
  • Oral selective inhibitor of exportin 1 (XPO1) – Selinexor
• Adverse events management – Identification of AEs associated with novel therapies and best practices for managing AEs
  • Cytokine Release Syndrome (CRS)
    • CRS – Cardiovascular complications
    • Surveillance for Cardiovascular Toxicity
    • CRS management
      • Tocilizumab
      • Corticosteroids
      • Supportive Care
  • Movement and neurocognitive treatment-emergent adverse events (MNTs)
    • Preventive strategies
    • Monitoring strategies
    • Management strategies

Intended Audience

---

Medical oncologists, pathologists, physician assistants, nurse practitioners, nurses, and other healthcare professionals who treat patients with DLBCL.

Commercial Supporter

---

This activity is supported by an educational grant from Pfizer